Crossmark

Inhibition of nucleo-cytoplasmic proteasome translocation by the aromatic amino acids or silencing Sestrin3—their sensing mediator—is tumor suppressive

Crossref DOI link: https://doi.org/10.1038/s41418-024-01370-x

Published Online: 2024-09-12

Published Print: 2024-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Livneh, Ido http://orcid.org/0000-0001-5530-7964
Fabre, Bertrand

Goldhirsh, Gilad

Lulu, Chen

Zinger, Adar

Shammai Vainer, Yael

Kaduri, Maya

Dahan, Aviva

Ziv, Tamar http://orcid.org/0000-0003-4299-7454
Schroeder, Avi

Ben-Neriah, Yinon http://orcid.org/0000-0003-1660-715X
Zohar, Yaniv

Cohen-Kaplan, Victoria

Ciechanover, Aaron http://orcid.org/0000-0001-9184-8944
Funding

Funding for this research was provided by:

Foulkes Foundation

European Molecular Biology Organization

Israel Science Foundation

Israel Cancer Research Fund

Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
License Information

Text and Data Mining valid from 2024-09-12

Version of Record valid from 2024-09-12
More Information

Article History

Received: 16 April 2024

Revised: 11 August 2024

Accepted: 27 August 2024

First Online: 12 September 2024

Competing interests

: IL and AC are co-founders of Tripod Therapeutics Ltd., which develops YWF-based therapies.

: All methods were performed in accordance with the relevant guidelines and regulations. The Institutional Animal Care and Utilization Committee of the Technion approved all animal experiments used in this study (approval number IL-053-04-21). Humans did not participate in this study, and therefore no informed consent was obtained.

Document is current

Any future updates will be listed below